Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.680 +0.050 (+0.75%)

Delayed Quote Updated: 1:09 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

2 Russell 2000 stocks on our watchlist and 1 we ignore

Today 0:38 EDT

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

October 22, 2026

Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgery

From Myriad Genetics, Inc.

Via GlobeNewswire

Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner

October 21, 2026

Check out the companies making headlines yesterday: Washington Trust Bancorp (NASDAQ:WASH): Regional bank Washington Trust Bancorp (NASDAQ:WASH) rose by 5% o...

Via StockStory

Top US Stock Movers: Today's Session Gainers and Losers ↗

October 20, 2026

Via Chartmill

Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session ↗

October 20, 2026

Via Chartmill

Gap Stocks: Gap-Up and Gap-Down Movers in Today's Session ↗

October 20, 2026

Via Chartmill

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

October 20, 2026

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 22.2% in the pre-market session after the company agreed to sell its Pr...

Via StockStory

Topics Artificial Intelligence

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

October 20, 2026

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

From Myriad Genetics, Inc.

Via GlobeNewswire

2 Small-Cap Stocks to Consider Right Now and 1 We Turn Down

October 19, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know

October 16, 2026

What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...

Via StockStory

Topics Bonds Economy

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

October 15, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

October 14, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...

Via StockStory

Topics Artificial Intelligence

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

October 08, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

October 07, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...

Via StockStory

Topics Artificial Intelligence

Why Is Myriad Genetics (MYGN) Stock Soaring Today

October 02, 2026

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin rais...

Via StockStory

1 Volatile Stock on Our Buy List and 2 We Question

October 02, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be...

Via StockStory

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

September 24, 2026

Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&...

Via StockStory

Topics Bankruptcy

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...

Via StockStory

Topics Artificial Intelligence

September 17, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

September 16, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

2 Unprofitable Stocks to Research Further and 1 We Find Risky

September 15, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)

September 07, 2026

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th...

Via StockStory

Topics Artificial Intelligence

Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter

September 02, 2026

Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell by 6.2% on Tues...

Via StockStory

Topics Economy

Why Myriad Genetics (MYGN) Stock Is Down Today

September 01, 2026

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the s...

Via StockStory

Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

August 27, 2026

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next f...

Via StockStory

Topics Artificial Intelligence

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

August 27, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics and Moderna Shares Plummet, What You Need To Know

August 24, 2026

What Happened? A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure prof...

Via StockStory

1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm

August 18, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

Topics Artificial Intelligence

Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks

August 17, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.